Lifecore Biomedical Announces CFO Transition
Lifecore Biomedical, Inc. (NASDAQ: LFCR), a comprehensive contract development and manufacturing organization (CDMO), has revealed a significant change in its leadership team. John Morberg will be stepping down from his position as Chief Financial Officer to explore new professional opportunities and to dedicate more time to his family. His departure is effective immediately, and financial executive Ryan Lake will assume the role. This transition represents a crucial moment for the company as it continues to pursue its mission within the CDMO sector.
Details of the Leadership Transition
John Morberg has been a dedicated CFO at Lifecore, managing numerous complex financial transactions and playing a vital role in the company's shift toward a focused CDMO model. Paul Josephs, the president and CEO of Lifecore, expressed his heartfelt appreciation for John's invaluable contributions during his time with the company, highlighting how his leadership has been instrumental in guiding Lifecore through significant growth phases.
Introducing Ryan Lake
In welcoming Ryan Lake as the new CFO, Josephs emphasized Ryan's extensive experience in the CDMO industry. His previous role as CFO at another CDMO has equipped him with unique insights and strategies that align well with Lifecore's goals. Ryan's expertise will be crucial as the company refines its strategic plans to seize opportunities in the CDMO market.
Ryan Lake's Background and Experience
Ryan Lake comes to Lifecore with a strong background in leadership roles within the pharmaceuticals and medical devices sectors. He has played a key role in significant mergers and acquisitions, successfully raising over $700 million in capital and navigating complex financial landscapes. His tenure as CFO at Societal CDMO was marked by strategic initiatives that transformed the company into a dedicated CDMO focused on efficient manufacturing and innovative therapeutic development.
A Strategic Vision for Growth
As Lifecore embarks on its next chapter, the combination of Lake's strategic financial management capabilities and the company’s commitment to delivering exceptional value in the CDMO space creates an optimistic outlook for future growth. Josephs reaffirmed the company's dedication to transparency and stakeholder engagement, which will be further strengthened under Lake’s leadership.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (NASDAQ: LFCR) specializes in the development and manufacturing of sterile injectable pharmaceutical products, including complex formulations. With over 40 years of experience in the biopharmaceutical manufacturing industry, the company serves as a reliable partner for both established and emerging biopharmaceutical firms. Lifecore is recognized for its high-quality injectable-grade hyaluronic acid and is dedicated to advancing innovative therapies.
Frequently Asked Questions
Who is the new CFO of Lifecore Biomedical?
Ryan Lake has been appointed as the new Chief Financial Officer of Lifecore Biomedical, succeeding John Morberg.
Why did John Morberg step down as CFO?
John Morberg decided to step down to pursue other professional opportunities and to spend more time with his family.
What qualifications does Ryan Lake bring to Lifecore Biomedical?
Ryan Lake has extensive experience in the CDMO sector, having previously served as CFO at Societal CDMO, where he contributed to significant corporate transformations.
What does Lifecore Biomedical specialize in?
Lifecore Biomedical specializes in the development and manufacturing of sterile injectable pharmaceutical products and offers unique capabilities in complex formulation processes.
How long has Lifecore Biomedical been in operation?
Lifecore Biomedical has over 40 years of experience in the biopharmaceutical manufacturing industry, establishing itself as a key player in the market.
